跳至主要内容
临床试验/EUCTR2004-003870-27-SE
EUCTR2004-003870-27-SE进行中(未招募)1 期

The Efficacy of Nitric Oxide in Stroke (ENOS) Trial: A prospective, collaborative, international, multicentre, randomised, parallel-group, single and outcome blinded, controlled, factorial trial to investigate the safety and efficacy of treatment with transdermal glyceryl trinitrate, a nitric oxide donor, and of continuing or stopping temporarily pre-stroke antihypertensive therapy, in patients with acute stroke - ENOS

niversity of Nottingham0 个研究点目标入组 4,011 人开始时间: 2011年11月30日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
4,011

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • a) Adult (age > 18 years).
  • b) Clinical stroke syndrome with limb weakness lasting at least 1 hour (i.e. not likely to be a
  • transient ischaemic attack).
  • c) Residual limb weakness at the time of enrolment (SSS Arm <6 and/or Leg <6, appendix C).
  • d) Onset < 48 hours. If the time of onset is unknown, apply the time when the patient was last
  • known to be well. [This timeframe covers the period of maximum uncertainty over altering
  • blood pressure and should permit the vast majority of otherwise eligible patients to be
  • e) Conscious (Glasgow Coma Scale > 8).
  • f) Systolic blood pressure in range 140 mmHg to 220 mmHg inclusive on the basis of at least
  • one of the three baseline pre-randomisation measures.
  • g) Independent prior to stroke (pre-morbid modified Rankin Scale < 2).
  • h) Meaningful consent, or assent from a relative or carer if the patient is unable to give
  • meaningful consent (e.g. in cases of dysphasia, confusion, or reduced conscious level).
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 1600
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 3200

排除标准

  • a) Definite need for nitrate therapy: e.g. concurrent myocardial infarction, unstable angina, left
  • ventricular failure. Patients admitted on nitrates for the management of stable angina may
  • stop these for the 7 day trial treatment period. b) Contraindication to nitrate therapy: e.g. hypersensitivity to nitrates, dehydration,
  • hypovolaemia, hypertrophic obstructive cardiomyopathy, aortic stenosis, cardiac
  • tamponade, constrictive pericarditis, mitral stenosis, marked anaemia, closed-angle
  • glaucoma, sildenafil (Viagra) or related drug, within 24 hours.
  • c) Definite need for pre-stroke antihypertensive, anti-anginal or anti-heart failure medication:
  • e.g. concurrent angina, heart failure.
  • d) Definite need for new antihypertensive, anti-anginal or anti-heart failure medication during
  • acute stroke: e.g. concurrent angina, heart failure, hypertensive encephalopathy, aortic
  • dissection.
  • e) Patients expected, on the basis of existing investigations, to require surgical intervention
  • (e.g. clot evacuation, carotid endarterectomy) during the treatment or follow-up period.
  • f) Known intracerebral pathology other than stroke, e.g. subarachnoid haemorrhage, brain
  • tumour, cerebral abscess.
  • g) Other serious condition which is likely to prevent outcome assessment at 90 days, e.g.
  • advanced cancer.
  • h) Previous enrolment in ENOS.
  • i) Current involvement in another trial of an experimental drug. [Patients may be randomised
  • into observational studies or non-drug trials.]
  • j) Not available for follow-up, e.g. no fixed address, overseas visitor.
  • k) Females of childbearing potential where pregnancy cannot be excluded by a negative
  • pregnancy test, pregnancy, or breastfeeding.
  • l) Need for new antihypertensive therapy to lower systolic blood pressure to achieve the
  • enrolment range of 140-220mmHg
  • m) New (not prescribed pre-stroke) antihypertensive medication commenced after stroke onset

研究者

发起方
niversity of Nottingham

相似试验

ENOS | 临床试验